Side-by-side · Research reference

AOD-9604vsMGF

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/47 cited

BAnimal-StrongHUMAN-REVIEWED14/55 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2000

~30 minHalf-life

SQ · Abdomen · Daily fasted

MGF

IGF-1Ec Splice Variant · Muscle-Specific

IGF-1EcSplice variantArmakolas 2016

24-AASynthetic E-domain

Animal onlyHuman evidence

SQ · Research context only

01Mechanism of Action

Parameter

AOD-9604

MGF

Primary target

β3-adrenergic receptor (proposed)Ng 2000

Satellite cells (Pax7+) in skeletal muscleMoore 2018

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2000

Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Satellite cell proliferation, myoblast differentiation, muscle fiber repair

Feedback intact?

No GH-axis or IGF-1 feedback

—

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2000

Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016 Vassilakos 2017

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

MGF

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

—

Frequency

Once daily, fasted

—

Lower / starter dose

150 mcg / day

—

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2000

Animal models + in vitro only

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

—

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

—

Half-life

~30 min plasma

—

Synthetic peptide

—

24-amino-acid E-domain sequence

Corresponds to human IGF-1Ec exons 4-6 region.

Rodent cardiac model

—

200 μg/kg via peptide-eluting microstructures

Post-MI injection; improved ejection fraction by 8 weeks.

Acute delivery (mouse MI)

—

Single bolus within 12 hrs post-infarctionShioura 2014

Delayed decompensation; no human protocol established.

Human evidence

—

None — no published clinical trials

All dosing extrapolated from animal models.

Detection in doping

—

Full-length MGF detected via LC-MS in illicit productsThevis 2014

WADA-prohibited since 2005; no therapeutic indication.

04Side Effects & Safety

Parameter

AOD-9604

MGF

Injection site reaction

Mild erythema

—

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

—

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

—

Pregnancy / OB

Avoid

—

Human safety data

—

None — no clinical trials published

Theoretical IGF-1 axis risk

—

Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)

Tumor promotion

—

IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer

Antibody development

—

Unknown — no longitudinal human exposure data

Local injection reaction

—

Presumed similar to other peptides (erythema, induration) — no direct evidence

Dysregulated expression with age

—

Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

MGF

·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
·No established therapeutic use — investigational only

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

MGF

·Family history of IGF-1-axis malignancies
·Use outside research setting

05Administration Protocol

Parameter

AOD-9604

MGF

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015 Shioura 2014

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014

5. Needle

29–31G, 4–8 mm insulin syringe.

Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

MGF

+ BPC-157

Multi-pathway

View BPC-157 →

MGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.

MGF: No established dose
BPC-157: 250–500 mcg SQ near injury site
Context: Animal models only
Primary benefit: Theoretical multi-tissue repair (muscle + tendon/ligament)

+ TB-500

Moderate

View TB-500 →

TB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.

MGF: No established dose
TB-500: 2–5 mg SQ weekly
Context: Animal models only
Primary benefit: Satellite cell activation + enhanced migration/angiogenesis